Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorÖztürk, Ahmet Alper
dc.contributor.authorBanderas, Lucia Martin
dc.contributor.authorOtero, Maria D. Cayero
dc.contributor.authorYenilmez, Evrim
dc.contributor.authorSenal, Behiye
dc.contributor.authorYazan, Yasemin
dc.date.accessioned2019-10-19T16:02:38Z
dc.date.available2019-10-19T16:02:38Z
dc.date.issued2019
dc.identifier.issn1596-5996
dc.identifier.urihttps://dx.doi.org/10.4314/tjpr.v18i1.1
dc.identifier.urihttps://hdl.handle.net/11421/13850
dc.descriptionWOS: 000457490100001en_US
dc.description.abstractPurpose: To design, formulate and characterize sustained-release formulations of dexketoprofen trometamol (DT) nanoparticles (NPs) Methods: Dexketoprofen trometamol (DT)-loaded poly(lactic-co-glycolic acid) (PLGA) NPs were produced by double emulsion-solvent evaporation method. The NPs were variously characterized for drug loading and release, particle profile, as well as by thermal analysis, x-ray difraction (XRD), Fourier transform infrared spectroscopy (FTIR) and nuclear magnetic resonance analysis (H-1-NMR). Furthermore, the NPs were evaluated for cytotoxicity against NIH-3T3 cells by 3-(4, 5-dimethylthiazol-2-Yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Results: The DT-loaded NPs demonstrated nanostructural characteristics and extended drug release. Particle size was in the range of 243 and 295 nm which remained unchanged in drug stability testing in simulated gastrointestinal media. Encapsulation efficiency ranged from 49 - 64 % for all the formulations. Higuchi and Korsmeyer-Peppas were the best-fit release kinetic models for the NPs containing 5 and 10 % DT, respectively. The NPs with 10 % DT presented no significant cytotoxicty at the doses and periods studied. Conclusion: Stable and non-toxic DT NPs with potential for sustained and controlled release of the drug have been successfully developed.en_US
dc.description.sponsorshipAnadolu University Scientific Research Project Foundation [1708S471]; Faculty of Scienceen_US
dc.description.sponsorshipThis study was financed by Anadolu University Scientific Research Project Foundation (no. 1708S471). The authors would like to thank Abdi Ibrahim (Istanbul, Turkey) for kindly providing DT. Faculty of Science is acknowledged for XRD, DOPNALAB Faculty of Pharmacy for FTIR and <SUP>1</SUP>H-NMR and AUBIBAM for SEM analyses. We also thank University of Seville, Faculty of Pharmacy, Department of Pharmacy and Pharmaceutical Technology for making available their facilities for this work.en_US
dc.language.isoengen_US
dc.publisherPharmacotherapy Groupen_US
dc.relation.isversionof10.4314/tjpr.v18i1.1en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDexketoprofen Trometamolen_US
dc.subjectPoly-Lactic-Co-Glycolic Acid (Plga)en_US
dc.subjectNanoparticlesen_US
dc.subjectRelease Kineticsen_US
dc.subjectStabilityen_US
dc.titleDexketoprofen trometamol-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles: Preparation, in vitro characterization and cyctotoxityen_US
dc.typearticleen_US
dc.relation.journalTropical Journal of Pharmaceutical Researchen_US
dc.contributor.departmentAnadolu Üniversitesi, Eczacılık Fakültesi, Farmasötik Teknoloji Anabilim Dalıen_US
dc.identifier.volume18en_US
dc.identifier.issue1en_US
dc.identifier.startpage1en_US
dc.identifier.endpage11en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US]
dc.contributor.institutionauthorYazan, Yasemin


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster